IPO/Presse: Bei Novartis verdichten sich Anzeichen für Alcon-Börsengang

ZÜRICH (dpa-AFX) – Seit Anfang 2017 warten Investoren darauf, dass Novartis seine strategische Überprüfung der Augensparte …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
656